Ustekinumab (SC injection)
Indication
Moderate to severe plaque psoriasis (NICE TA180)
NICE TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis
Red
Brand:
Stelara
Nice TA:
180
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Skin
Background
LMMG is adopting the local decisions made prior to April 2013.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: